

Cite this: *Chem. Sci.*, 2025, 16, 11508

All publication charges for this article have been paid for by the Royal Society of Chemistry

# Synthesis of polysubstituted cyclobutanes through a photoredox strain-release/[3,3]-rearrangement cascade†

Fangqing Zhang,<sup>‡ab</sup> Chun Xu,<sup>‡bc</sup> Zichun Zhang,<sup>b</sup> Zhuang Yang,<sup>d</sup> Tao Peng,<sup>id a</sup> Wen Shao,<sup>id \*c</sup> Xiaoming Feng<sup>id \*be</sup> and Yangbin Liu<sup>id \*ab</sup>

Small saturated carbocycles, such as cyclobutanes, with elevated three-dimensionality and rich C<sub>sp3</sub> centers are privileged scaffolds in naturally occurring molecules and drug discovery. It remains highly desirable and challenging to develop modular and straightforward strategies to craft densely substituted cyclobutanes. Herein, a photoredox-catalyzed radical strain-release/[3,3]-rearrangement cascade (SRRC) strategy for efficient synthesis of polysubstituted cyclobutanes is disclosed. This protocol operates with readily available  $\alpha$ -silylamines as radical precursors, and strained bicyclo[1.1.0]butanes (BCBs) and cyclobutenes as radical acceptors, to access an array of structurally diverse 1,1,3- and 1,1,2-trisubstituted cyclobutanes containing a unique non-natural amino acid scaffold. Mechanistic studies reveal the pivotal reactivity of the silylketene acetal intermediate and the origin of diastereoselectivity. The power and utility of this method are illustrated with diverse transformations and preliminary anticancer assessment.

Received 22nd February 2025

Accepted 13th May 2025

DOI: 10.1039/d5sc01431j

rsc.li/chemical-science

## Introduction

Polysubstituted cyclobutanes are not only prevalent in natural products, but also serve as privileged motifs in drug molecules (Fig. 1a).<sup>1</sup> Compared to the common planar systems, cyclobutane cores possess a more rigid three-dimensionality and an increased content of C<sub>sp3</sub> centers, thus exhibiting a greater structural modularity and enhanced pharmacologically relevant properties.<sup>2</sup> As such, angiotensin (1–7) analogs containing a non-natural amino acid [*cis*-3-(aminomethyl)cyclobutanecarboxylic acid (ACCA)] are used as effective therapeutic compositions to treat or prevent a broader range of diseases.<sup>1c</sup> Consequently, development of efficient and modular strategies

to construct polysubstituted cyclobutanes remains a fundamentally important research topic and has attracted substantial attention from synthetic chemists.

Among various approaches to prepare cyclobutanes (Fig. 1b), such as [2 + 2] cycloaddition,<sup>3</sup> C–H functionalization<sup>4</sup> and ring contraction/expansion,<sup>5</sup> strain-release-driven syntheses have been popularized and emerged as a divergent strategy to build complex cyclobutanes. Particularly, bicyclo[1.1.0]butanes (BCBs) and cyclobutenes are two privileged building blocks in efficient access to cyclobutane scaffolds under mild conditions due to their relatively high ring-strain energies.<sup>6–13</sup> However, developing straightforward and potent strategies for the simultaneous installation of two functional groups into these strained rings to rapidly assemble polysubstituted cyclobutanes still poses significant challenges.<sup>14,15</sup>

The strain-release/rearrangement cascade (SRRC) strategy provides an effective approach for achieving regioselective difunctionalization of BCBs, thereby affording more densely polysubstituted cyclobutanes (Fig. 1c). For example, Aggarwal and coworkers reported the addition of electron-deficient species (aryl palladium, allyl iridium, electrophilic radicals) to the strained C–C  $\sigma$ -bond, triggering a 1,2-boronate rearrangement to produce 1,1,3-trisubstituted cyclobutanes.<sup>16</sup> Glorius and coworkers described the addition of sulfur radical cations to BCBs and subsequent alkynyl rearrangement by C–S  $\sigma$ -bond scission, leading to the thio-alkynyl difunctionalization of BCBs.<sup>17</sup> Although such advances have been made in the SRRC strategy, they are still limited to electrophilic species as initiators. Additionally, BCBs as highly strained molecules can undergo thermally driven ring-opening reactions with

<sup>a</sup>State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, Guangdong, 518055, China

<sup>b</sup>Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, 518055, China. E-mail: liuyb@szbl.ac.cn


<sup>c</sup>Key Laboratory for Green Organic Synthesis and Application of Hunan Province, Key Laboratory of Environmentally Friendly Chemistry and Application of Ministry of Education, College of Chemistry, Xiangtan University, Xiangtan 411105, China. E-mail: shaowen@xtu.edu.cn

<sup>d</sup>Laboratory of Natural and Targeted Small Molecule Drugs, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China

<sup>e</sup>Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, 610064, China. E-mail: xmfeng@scu.edu.cn

† Electronic supplementary information (ESI) available. CCDC 2403838 and 2403839. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d5sc01431j>

‡ These authors contributed equally to this work.



**Fig. 1** Importance and chemistry of cyclobutanes. (a) Privileged cyclobutane scaffold in drug molecules and natural products. (b) Representative synthetic strategies for constructing cyclobutanes. (c) Selected SRRC examples to enable difunctionalization of strained BCs. (d) This work: development of a photoredox radical SRRC method to access site-divergent synthesis of 1,3-/1,2-difunctionalized cyclobutanes. Cy, cyclohexyl. EWG, electron withdrawing group. MG, migration group. [Si], silyl group.

nucleophiles,<sup>4e,8,18</sup> and can also couple with single-electron radical nucleophiles for the ring-opening processes.<sup>9b-d,19</sup> This reactivity was exemplified by the pioneering works of Cintrat and Jui,<sup>9c,19a</sup> who independently reported the addition of nucleophilic  $\alpha$ -amino radicals to BCBs, yielding hydroalkylated cyclobutanes in moderate to good yields. Nevertheless, the combination of nucleophilic strain-release and rearrangement cascade transformations in BCBs to achieve difunctionalization and produce polysubstituted cyclobutanes remains unexplored.

Recently, our group has disclosed a photocatalytic radical dearomatization of indoles and [3,3]-rearrangement cascade reaction to produce valuable prenylated indolines.<sup>20</sup> Inspired by this precedent, we envisioned that the nucleophilic radicals (for instance,  $\alpha$ -aminoalkyl radicals) could add to the central C–C  $\sigma$ -bond of BCBs driven by strain-release force. Subsequent single-electron reduction could generate a ketene acetal intermediate and trigger an intramolecular Claisen-type [3,3]-rearrangement, thus enabling regioselective synthesis of 1,1,3-trisubstituted cyclobutanes (Fig. 1d, left). Should this approach prove successful, it would conveniently incorporate two privileged motifs, amino and allyl, into a saturated carbocycle to produce novel non-natural amino acids containing the polysubstituted

cyclobutane skeleton. Moreover, the complementary 1,1,2-trisubstituted cyclobutanes could be easily accessed by trapping with cyclobutene partners, followed by a similar procedure (Fig. 1d, right). A major challenge of this cascade process would be the competition between [3,3]-rearrangement and protonation of the active ketene acetal intermediate. Herein, we report a nucleophilic radical-induced SRRC reaction of BCBs and cyclobutenes to forge 1,1,3- and 1,1,2-trisubstituted cyclobutane products, respectively. This protocol covers a range of readily available amines with high functional group tolerance and a variety of allyl fragments, such as geranyl, farnesyl and allenyl. The synthetic utility of the resulting products is also demonstrated by further transformations to form versatile building blocks.

## Results and discussion

### Reaction development

Given that prenyl and reverse-prenyl motifs are widely found in bioactive natural products and medicinal compounds,<sup>21</sup> our design plan began with a prenyl bicyclo[1.1.0]butane-1-carboxylate **1** as the radical acceptor, potentially producing



reverse-prenyl-functionalized cyclobutanecarboxylic acid after the desired radical SRRC process. For radical donors, tertiary amines containing a trimethylsilyl (TMS) functionality are suitable precursors (**2**) in photoredox reactions:<sup>22,23</sup> (1) they have relatively low oxidation potentials to readily generate highly nucleophilic  $\alpha$ -aminoalkyl radicals; (2) the fragment TMS can combine with the ketene acetal species and promote the subsequent [3,3]-rearrangement; (3) organic amines have a rich structural diversity in FDA approved drugs, thus making the amine-functionalized cyclobutanes even more valuable in drug discovery. Preliminary optimization experiments highlighted **PC1** as the optimal photocatalyst with a moderate oxidation potential, providing the amino- and reverse-prenyl 1,3-difunctionalized cyclobutane product **3** in 30% yield (Fig. 2). Notably, such congested vicinal quaternary centers in product **3** were constructed smoothly due to the inherent intramolecular advantages of [3,3]-sigmatropic rearrangement. Further investigation of other photocatalysts with a higher or lower oxidation potential led to an unproductive reaction (**PC2-4**). During the selection of the ideal **PC**, we found that amine **2** was almost fully consumed and the majority of BCB **1** was left. It is assumed that the desired radical strain-release addition of BCB is slower than the decomposition rate of the  $\alpha$ -aminoalkyl radical. Thus, we changed the ratio between **1** and **2** to achieve a higher yield (from 30% to 50%) as the amount of BCB increased (2.0 equiv.). Examination of different solvents identified CH<sub>3</sub>CN as the optimal solvent for this transformation. Delightedly, fine-tuning of the reaction parameters revealed that a higher concentration was the most beneficial to improve reactivity (86% yield at 0.8 M). Additional control experiments confirmed that both the photocatalyst and visible light were essential for the desired product.




Fig. 2 Investigation of the photocatalytic SRRC reaction of BCB. Reaction conditions: unless otherwise noted, **1** (0.1 mmol), **2** (0.12 mmol), **PC** (1.5 mol%) in CH<sub>3</sub>CN (0.1 M), 24 h, 450 nm at 40 °C. The yields are determined by <sup>1</sup>H NMR analysis of the crude product mixtures. In all cases, the product d.r. is approximately 1.4 : 1. Excited photocatalyst half potentials are given against SCE. (a) Changing the substrate ratio as **1** (0.2 mmol), **2** (0.1 mmol). (b) For ease of separation, the carboxylic acid is converted to its methyl ester by TMSCHN<sub>2</sub>. The isolated yield of the two-step process is reported.

## Substrate scope for the synthesis of 1,1,3-trisubstituted cyclobutanes

With the optimized conditions in hand, we next evaluated the substrate scope of this photocatalytic SRRC reaction of BCBs to afford 1,1,3-trisubstituted cyclobutanes (Fig. 3). Various substituted *N,N*-dimethyl anilines (**5–13**) were well tolerated to give the corresponding cyclobutane products in moderate to good yields. A series of functional groups including electron-withdrawing and electron-donating groups on the aromatic ring, such as halogens, cyano and methoxy groups, were well tolerated. Altering the substituent on the nitrogen atom, ethyl (**14**), isopropyl (**15**), allyl (**16**), and phenyl (**17** and **18**) groups were also compatible with this protocol. Under the same conditions, carbazole (**19**) and 5*H*-dibenzo[*b,f*]azepine (**20**) were incorporated into the cyclobutane scaffold, albeit in slightly lower yields. Additionally, alkyl amines as substrates were shown to perform similarly, delivering the corresponding cyclobutylated amino acid products in good yields (**21–24**). Given the frequency and importance of nitrogen-containing saturated heterocycles in drug development, we sought to evaluate the tolerance of various *N*-heterocyclic functionalities. As such, piperidines bearing functional groups, 1*H*-azepine, morpholine, piperazine, 1,4-diazepane, and tetrahydroquinoline readily participated in the radical addition/rearrangement cascade transformation, providing the desired products smoothly (**25–33**). The structure and relative configuration were unambiguously confirmed by X-ray crystallographic analysis of **31**. Next, we turned our attention to BCB acceptors. By varying diverse allylic esters as substrates, this protocol was successfully extended to achieve allyl segment diversification beyond the reverse-prenyl group, such as unsubstituted allyl (**34**), 2-methyl substituted allyl (**35**), valuable allenyl group (**36**, from propargylic esters), geranyl (**37**), and even more complex farnesyl (**38**). Further generality for the developed method was demonstrated in more systems with biologically relevant scaffolds. Remarkably, such core amino-fragments in flunarizine (**39**), bepotastine (**40**) and serotonin reuptake inhibitor duloxetine (**41**) underwent this transformation smoothly, affording the corresponding cyclobutylated amino acid products in moderate yields.

## Substrate scope for the synthesis of 1,1,2-trisubstituted cyclobutanes

Having established the above process for accessing C3-aminoalkyl-type cyclobutanes *via* the radical addition to the central C–C  $\sigma$ -bond of BCBs, we wondered if the complementary site-isomers, C2-aminoalkyl-functionalized cyclobutanes, would be obtained through the radical addition to the C=C bond of cyclobutenes, followed by a [3,3]-rearrangement reaction. Pleasingly, this protocol was compatible to access 1,2-difunctionalization of cyclobutenes with minor adjustments in the reaction setup (Fig. 4). Aniline and *N*-heterocyclic amine derivatives could be well tolerated, such as piperidine, morpholine, piperazine, and complex bioactive motifs (**42–47**). It is worth mentioning that aminoalkyl and reverse-prenyl were incorporated into cyclobutanes in an *anti*-selective manner,






Fig. 3 Substrate scope for the synthesis of 1,1,3-trisubstituted cyclobutanes. Reaction conditions: unless otherwise noted, 1 (0.4 mmol, 2.0 equiv.), 2 (0.2 mmol, 1.0 equiv.), PC1 (1.5 mol%) in CH<sub>3</sub>CN (0.8 M), 24 h, 450 nm at 40 °C. Some products are transferred into their methyl ester for the ease of separation. Methyl esterification conditions: TMSCHN<sub>2</sub> (4.0 equiv.), Et<sub>2</sub>O/MeOH (4 : 1), 2 h, room temperature. Isolated yields are reported. In most cases, the product d.r. is approximately 1.4 : 1.








Fig. 4 Substrate scope for the synthesis of 1,1,2-trisubstituted cyclobutanes. Reaction conditions: unless otherwise noted, 4 (0.2 mmol, 1.0 equiv.), 2 (0.4 mmol, 2.0 equiv.), PC1 (1.5 mol%) in CH<sub>3</sub>CN (0.8 M), 12 h, 450 nm at 40 °C. Isolated yields are reported.

providing 1,1,2-trisubstituted cyclobutane products in excellent diastereoselectivities (20:1 d.r. for most cases). Moreover, different cyclobutene derivatives bearing diverse allylic esters were also reactive, providing the corresponding allenyl, simple allyl, or 2-methyl-allyl products in good yields (48–53).

### Mechanistic investigation

As shown in Fig. 5a, possible mechanistic details on the photoredox radical SRRC process are proposed. Firstly, single-electron transfer (SET) between the excited Ir(III) photocatalyst PC1 and α-silylaniline 2 should generate radical cation I that undergoes fragmentation to form an α-aminoalkyl radical II and a trimethylsilylium ion stabilized by acetonitrile solvent. Then, the strain-release addition of this highly nucleophilic species II to the BCB (1) would produce α-ester radical III. The subsequent reduction by the Ir(II) catalyst would give enolate IV, which could combine with a trimethylsilylium ion to form the key silylketene acetal intermediate V. Then, the Claisen-type [3,3]-rearrangement of V would furnish the 1,1,3-trisubstituted cyclobutane product 3. Similarly, the synthesis of 1,1,2-trisubstituted cyclobutanes could be achieved through a radical addition to cyclobutene followed by the corresponding rearrangement pathway.

To gain insights into the above mechanism, a series of control experiments and spectroscopy studies were conducted. First, a light on/off experiment showed that continuous irradiation was essential for product formation (Fig. 5b). UV/vis absorption experiments confirmed the primary absorption of the photocatalyst at the irradiated wavelength (for details, see

the ESI†). Stern–Volmer luminescence quenching revealed that the excited state of PC1 was significantly quenched by the α-silylaniline (Fig. 5c). Then, such a radical addition/rearrangement process was completely inhibited in the presence of 2,2,6,6-tetramethylpiperidinyloxy (TEMPO) and the corresponding TEMPO-aminoalkyl adduct was confirmed by HRMS (Fig. 5d, for details, see the ESI†), suggesting the involvement of aminoalkyl radical species in product formation. Moreover, when the reaction was carried out with the addition of external water, the aminoalkylation-protonation products 54 and 55 were detected exclusively, while the [3,3]-rearrangement process was completely interrupted, which supports the generation of α-ester anion species IV (Fig. 5e). Interestingly, we also compared the reactivity difference between the BCB and cyclobutene by an intermolecular competition experiment. The cyclobutene 4 was proved to be more reactive than BCB 1, affording the corresponding rearrangement product 42 in 63% yield (Fig. 5f).

To further evaluate the reaction's energy profile and rationalize the observed reaction outcome, we performed density functional theory (DFT) calculations. As shown in Fig. 6a, the relative energies for morpholine radical (INT) addition to BCB 1 and cyclobutene 4 have been computed. It is found that the BCB as the radical acceptor with 20.4 kcal mol<sup>−1</sup> free energy of activation is energetically much higher than the cyclobutene scenario with a modest activation barrier (12.8 kcal mol<sup>−1</sup>, Fig. 6a). This result is in good accordance with the competition experiment observation that radical addition to the BCB is less kinetically favored than to the cyclobutene. To elucidate the observed reactivity difference, we conducted a comparative







Fig. 5 Mechanistic investigations and control experiment. (a) Proposed mechanism to explain the reaction pathway. (b) light on/off experiment. (c) Stern–Volmer plot showing  $\alpha$ -silylaniline **2** as the quencher. (d) radical-inhibition using TEMPO. (e) control experiment by adding  $\text{H}_2\text{O}$  to capture  $\alpha$ -ester anion species. (f) competition experiment between BCB **1** and cyclobutene **4**.

analysis of strain energies between BCBs and cyclobutenes. It is found that BCBs display a remarkable ring strain energy ( $64 \text{ kcal mol}^{-1}$ ), which is much higher than that of cyclobutenes ( $28.7 \text{ kcal mol}^{-1}$ ).<sup>6b</sup> As such, the strain energy is not the key factor leading to the enhanced reactivity of cyclobutenes. Further geometric analysis demonstrates distinct structural reorganization pathways: the BCB-to-cyclobutane conversion requires substantial geometric distortion, while the cyclobutene-to-cyclobutane transformation proceeds with minimal conformational changes (as evidenced by bond angle analysis). These structural insights suggest that the reduced geometric

perturbation during cyclobutene activation may contribute to the observed preference for radical addition to cyclobutenes over BCBs.

To gain insight into the origin of diastereoselectivity, possible [3,3]-rearrangement transition states of the silylketene acetal intermediate were also investigated. The computational analysis of BCB-radical intermediate **INT-TMS-A** suggests that it can undergo two transition states **TS-A1** and **TS-A2** with very close Gibbs free-energy ( $\Delta G = 18.0 \text{ kcal mol}^{-1}$  vs.  $18.2 \text{ kcal mol}^{-1}$ ), thus resulting in a similar ratio of *anti*-**INT-C1** and *syn*-**INT-C2** rearrangement products (Fig. 6b). These calculations



**Fig. 6** Insights from DFT calculations. (a) aminoalkyl radical addition to BCB and cyclobutene. (b) relative energies for [3,3]-rearrangement of the BCB-TMS intermediate. (c) relative energies for [3,3]-rearrangement of the (*E*)-cyclobutene-TMS intermediate. Calculations were performed at the B3LYP/6-31G(d,p)/SMD (acetonitrile) level of theory. More details on the [3,3]-rearrangement of cyclobutene-radical intermediate (*Z*)-INT-TMS-B are provided in ESI Fig. S7.†

explain why the SRRC process of BCBS tends to give the product in a low diastereomeric ratio (1.4 : 1 d.r., Fig. 3). Comparatively, the computational analysis of [3,3]-rearrangement involving the 2-aminoalkyl substituted cyclobutane was also conducted (Fig. 6c). By taking (*E*)-**INT-TMS-B** as an example, the transition state **TS-B1** that leads to the formation of the observed diastereomer *anti*-**INT-D1** is more kinetically favorable than the other transition state **TS-B1** by at least 3.9 kcal mol<sup>-1</sup>, which generates the diastereomer *syn*-**INT-D2**. This substantial energy difference suggests that the prenyl group prefers to approach the four-membered ring from the opposite direction of the morpholine substituent. The scenario of the (*Z*)-**INT-TMS-B** intermediate is also considered (see the SI for details).

Furthermore, Hirshfeld partition of molecular density (IGMH) analysis was performed to investigate the non-covalent

interactions in both transition states **TS-B1** and **TS-B2**. Notably, **TS-B2** suffers from the obvious steric repulsion due to the stronger CH $\cdots$ HC and CH $\cdots$ N interactions between the terminal methyl on the ally moiety and the morpholine fragment. Thus, the corresponding diastereomer bearing the reverse-prenyl and the morpholine in a *syn*-manner is unfavorable. These results are consistent with the experimental findings in Fig. 4, wherein the SRRC process of cyclobutene often affords an enhanced diastereoselectivity (for most cases 20 : 1 d.r.).


## Synthetic utility and biological activity evaluation

We next performed divergent synthetic manipulations of cyclobutane products to further reveal the potential utility of the enclosed functionalization protocol by taking advantage of the

functionalities, including carboxylic acid, terminal olefin and amino groups (Fig. 7a). Structurally appealing tripeptides **56** and **57** containing 1,3- and 1,2-cyclobutylated amino acids were readily achieved under the classical condensation conditions. The carboxylic acid group was also amenable to deliver primary alcohol **58** by  $\text{LiAlH}_4$  reduction and to engage in Schmidt rearrangement, giving rise to the cyclobutylated amine **59**. Iodine-mediated lactonization led to more complex cyclobutylated spiro-lactone **60** in 50% yield. Interestingly, when targeting the

preparation of an acyl chloride intermediate through the oxalyl chloride and DMF procedure, we obtained the unexpected yet attractive cyclobutane ring-fused lactam scaffold **61** in a single step. Lastly, the hydrogenation of the reverse-prenyl to a bulky *tert*-amyl group was furnished with a Pd/C catalyst (**62**). A sequential hydroboration-oxidation of the terminal olefin could formally introduce the isopentyl alcohol motif to cyclobutane (**63**).

Given that cyclobutanes are privileged in pharmaceuticals, we decided to evaluate the anticancer activity of selected



**Fig. 7** Diversification of cyclobutane products and biological activity study. (a) extension of the synthetic applications of the functionalized products. (b) TMD-8 inhibition induced by selected compounds at 10 μM for 72 h; IC<sub>50</sub> values of compound **31** in different cancer cell lines, including TMD-8, KPC and HCT-116. Human diffuse large B-cell lymphoma (TMD-8); mouse pancreatic ductal adenocarcinoma (KPC); human colorectal adenocarcinoma (HCT-116).



products by detecting the *in vitro* cytotoxicity against the human diffuse large B-cell lymphoma (TMD-8) cell line (Fig. 7b). Pleasingly, a series of cyclobutane products showcased preliminary inhibitory activity at 10  $\mu\text{M}$ . Among these candidates, cyclobutylated amino acid **31** bearing a piperazine motif displayed superior cytotoxicity to inhibit diverse cancer cell lines, including TMD-8, mouse pancreatic ductal adenocarcinoma (KPC) and human colorectal adenocarcinoma (HCT-116), with  $\text{IC}_{50}$  values ranging from 5.7 to 8.2  $\mu\text{M}$ . This indicates such cyclobutane compounds have potential applications in medicinal chemistry.

## Conclusions

In summary, we have established a photoredox-mediated radical strain-release/[3,3]-rearrangement cascade strategy to achieve polysubstituted cyclobutanes, with the utility of bicyclo[1.1.0]butanes and cyclobutenes as radical acceptors and readily available tertiary amines as radical donors. An array of structurally diverse 1,1,3- and 1,1,2-trisubstituted cyclobutanes containing a non-natural amino acid scaffold were smoothly accessed in moderate to good yields. This protocol features mild reaction conditions, good functional group tolerance, and an extremely wide range of amine precursors and allyl fragments. Mechanistic investigations reveal that the pivotal reactivity of the silylketene acetal intermediate is generated by the strain-release radical addition and subsequent single electron reduction. The origin of the *anti*-selective formation of densely substituted cyclobutanes *via* the steric repulsion effect in the transition states of [3,3]-rearrangement is explained by computational calculations. The synthetic applications and anticancer activity assessment further substantiate the potential of this photocatalytic SRRC protocol. We anticipate that the development of other types of transformations based on the SRRC strategy will expand the synthetic chemical space of saturated carbocycles.

## Data availability

The data that support the findings of this study are available in the ESI† of this article.

## Author contributions

F. Q. Z. performed the experiments and prepared the ESI.† C. X. investigated several substrates and performed some experiments. Z. C. Z. performed the DFT calculations. Z. Y. performed the biological experiments. T. P. helped with the Stern-Volmer luminescence quenching experiment. W. S. supported the project. X. M. F. supported the project. Y. B. L. designed and supervised the project, and wrote the manuscript. All the authors contributed to the manuscript revisions.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We appreciate the National Natural Science Foundation of China (22471174), Shenzhen Bay Laboratory (S201100003 and S211101001-4), Shenzhen Bay Qihang Fellow Program (QH23001), Guangdong Pearl River Talent Program (2021QN020268) and the Natural Science Foundation of Guangdong Province (2024A1515012381) for generous financial support.

## Notes and references

- (a) H.-M. Chung, Y.-H. Chen, M.-R. Lin, J.-H. Su, W.-H. Wang and P.-J. Sung, *Tetrahedron Lett.*, 2010, **51**, 6025–6027; (b) V. M. Dembitsky, *Phytomedicine*, 2014, **21**, 1559–1581; (c) M. D. Tricklebank, *Drugs*, 2000, **3**, 228–231; (d) M. R. Van Der Kolk, M. A. C. H. Janssen, F. P. J. T. Rutjes and D. Blanco-Ania, *ChemMedChem*, 2022, **17**, e202200020; (e) P. Gallagher, A. Tallant, D. Yohannes and K. A. Gruber, PCT Int. Patent Appl. US2016/066181, 2017.
- (a) F. Lovering, J. Bikker and C. Humblet, *J. Med. Chem.*, 2009, **52**, 6752–6756; (b) F. Lovering, *MedChemComm*, 2013, **4**, 515–519.
- For selected examples of construction of cyclobutanes by [2 + 2] cycloaddition, see: (a) S. Poplata, A. Tröster, Y.-Q. Zou and T. Bach, *Chem. Rev.*, 2016, **116**, 9748–9815; (b) F. Strieth-Kalthoff, M. J. James, M. Teders, L. Pitzer and F. Glorius, *Chem. Soc. Rev.*, 2018, **47**, 7190–7202; (c) M. R. Fructos and A. Prieto, *Tetrahedron*, 2016, **72**, 355–369; (d) S. Das, C. Zhu, D. Demirbas, E. Bill, C. K. De and B. List, *Science*, 2023, **379**, 494–499; (e) Y. Liu, D. Ni and M. K. Brown, *J. Am. Chem. Soc.*, 2022, **144**, 18790–18796; (f) Z. Liu, C. Zhou, T. Lei, X.-L. Nan, B. Chen, C.-H. Tung and L.-Z. Wu, *CCS Chem.*, 2020, **2**, 582–588; (g) Z. C. Girvin, L. F. Cotter, H. Yoon, S. J. Chapman, J. M. Mayer, T. P. Yoon and S. J. Miller, *J. Am. Chem. Soc.*, 2022, **144**, 20109–20117; (h) F. Pecho, Y. Sempere, J. Gramüller, F. M. Hörmann, R. M. Gschwind and T. Bach, *J. Am. Chem. Soc.*, 2021, **143**, 9350–9354.
- (a) K.-J. Xiao, D. W. Lin, M. Miura, R.-Y. Zhu, W. Gong, M. Wasa and J.-Q. Yu, *J. Am. Chem. Soc.*, 2014, **136**, 8138–8142; (b) W. R. Gutekunst and P. S. Baran, *J. Am. Chem. Soc.*, 2011, **133**, 19076–19079; (c) L. M. Chapman, J. C. Beck, L. Wu and S. E. Reisman, *J. Am. Chem. Soc.*, 2016, **138**, 9803–9806; (d) F. Frébault and N. Maulide, *Angew. Chem., Int. Ed.*, 2012, **51**, 2815–2817; (e) R. A. Panish, S. R. Chintala and J. M. Fox, *Angew. Chem., Int. Ed.*, 2016, **55**, 4983–4987.
- (a) C. Liu, R. Chen, Y. Shen, Z. Liang, Y. Hua and Y. Zhang, *Angew. Chem., Int. Ed.*, 2017, **56**, 8187–8190; (b) R. Meier and D. Trauner, *Angew. Chem., Int. Ed.*, 2016, **55**, 11251–11255; (c) C. Hui, L. Brieger, C. Strohmman and A. P. Antonchick, *J. Am. Chem. Soc.*, 2021, **143**, 18864–18870; (d) F. Kleinbeck and F. D. Toste, *J. Am. Chem. Soc.*, 2009, **131**, 9178–9179; (e) X.-Z. Shu, M. Zhang, Y. He, H. Frei and F. D. Toste, *J. Am. Chem. Soc.*, 2014, **136**, 5844–5847.



- 6 (a) K. B. Wiberg, G. M. Lampman, R. P. Ciula, D. S. Connor, P. Schertler and J. Lavanish, *Tetrahedron*, 1965, **21**, 2749–2769; (b) J. Qi, C. Wang, G. Wang, P. O'Neill, S. Reddy Dubbaka, H. Ting Ang, X. Chen and J. Wu, *Angew. Chem., Int. Ed.*, 2025, **64**, e202413723.
- 7 For selected reviews on the functionalization of BCBs and cyclobutenes: (a) J. Chen, Q. Zhou, H. Fang and P. Lu, *Chin. J. Chem.*, 2022, **40**, 1346–1358; (b) X. Zhan, H.-X. He, Q. Peng and J.-J. Feng, *Synthesis*, 2024, **56**, 3829–3848; (c) M. Golfmann and J. C. L. Walker, *Commun. Chem.*, 2023, **6**, 9; (d) Y. Xiao, L. Tang, X.-C. Yang, N.-Y. Wang, J. Zhang, W.-P. Deng and J.-J. Feng, *CCS Chem.*, 2025, DOI: [10.31635/ccschem.025.202505825](https://doi.org/10.31635/ccschem.025.202505825).
- 8 R. Panish, S. R. Chintala, D. T. Boruta, Y. Fang, M. T. Taylor and J. M. Fox, *J. Am. Chem. Soc.*, 2013, **135**, 9283–9286.
- 9 (a) R. Gianatassio, J. M. Lopchuk, J. Wang, C.-M. Pan, L. R. Malins, L. Prieto, T. A. Brandt, M. R. Collins, G. M. Gallego, N. W. Sach, J. E. Spangler, H. Zhu, J. Zhu and P. S. Baran, *Science*, 2016, **351**, 241–246; (b) X. Wu, W. Hao, K.-Y. Ye, B. Jiang, G. Pombar, Z. Song and S. Lin, *J. Am. Chem. Soc.*, 2018, **140**, 14836–14843; (c) G. Ernouf, E. Chirkin, L. Rhyman, P. Ramasami and J.-C. Cintrat, *Angew. Chem., Int. Ed.*, 2020, **59**, 2618–2622; (d) X. Yu, M. Lübbesmeyer and A. Studer, *Angew. Chem., Int. Ed.*, 2021, **60**, 675–679; (e) M. Ociepa, A. J. Wierzbza, J. Turkowska and D. Gryko, *J. Am. Chem. Soc.*, 2020, **142**, 5355–5361; (f) L. Tang, Q.-N. Huang, F. Wu, Y. Xiao, J.-L. Zhou, T.-T. Xu, W.-B. Wu, S. Qu and J.-J. Feng, *Chem. Sci.*, 2023, **14**, 9696–9703; (g) G. Chen, D. Tian, X. Wang and H.-J. Zhang, *ACS Catal.*, 2024, **14**, 14928–14936; (h) A. Guin, S. Bhattacharjee, M. S. Harariya and A. T. Biju, *Chem. Sci.*, 2023, **14**, 6585–6591.
- 10 (a) Y.-J. Chen, T.-J. Hu, C.-G. Feng and G.-Q. Lin, *Chem. Commun.*, 2015, **51**, 8773–8776; (b) M. Guisán-Ceinos, A. Parra, V. Martín-Heras and M. Tortosa, *Angew. Chem., Int. Ed.*, 2016, **55**, 6969–6972; (c) S. Feng, H. Hao, P. Liu and S. L. Buchwald, *ACS Catal.*, 2020, **10**, 282–291; (d) F. W. Goetzke, A. M. L. Hell, L. van Dijk and S. P. Fletcher, *Nat. Chem.*, 2021, **13**, 880–886.
- 11 For selected examples of racemic peripheral cyclization of BCBs, see: (a) R. Kleinmans, T. Pinkert, S. Dutta, T. O. Paulisch, H. Keum, C. G. Daniliuc and F. Glorius, *Nature*, 2022, **605**, 477–482; (b) K. Dhake, K. J. Woelk, J. Becica, A. Un, S. E. Jenny and D. C. Leitch, *Angew. Chem., Int. Ed.*, 2022, **61**, e202204719; (c) Y. Liang, R. Kleinmans, C. G. Daniliuc and F. Glorius, *J. Am. Chem. Soc.*, 2022, **144**, 20207–20213; (d) R. Guo, Y.-C. Chang, L. Herter, C. Salome, S. E. Braley, T. C. Fessard and M. K. Brown, *J. Am. Chem. Soc.*, 2022, **144**, 7988–7994; (e) Y. Zheng, W. Huang, R. K. Dhungana, A. Granados, S. Keess, M. Makvandi and G. A. Molander, *J. Am. Chem. Soc.*, 2022, **144**, 23685–23690; (f) Y. Liang, F. Paulus, C. G. Daniliuc and F. Glorius, *Angew. Chem., Int. Ed.*, 2023, **62**, e202305043; (g) D. Ni, S. Hu, X. Tan, Y. Yu, Z. Li and L. Deng, *Angew. Chem., Int. Ed.*, 2023, **62**, e202308606; (h) R. Kleinmans, S. Dutta, K. Ozols, H. Shao, F. Schäfer, R. E. Thielemann, H. T. Chan, C. G. Daniliuc, K. N. Houk and F. Glorius, *J. Am. Chem. Soc.*, 2023, **145**, 12324–12332; (i) S. Agasti, F. Beltran, E. Pye, N. Kaltsayannis, G. E. M. Crisenza and D. J. Procter, *Nat. Chem.*, 2023, **15**, 535–541; (j) Y. Liu, S. Lin, Y. Li, J.-H. Xue, Q. Li and H. Wang, *ACS Catal.*, 2023, **13**, 5096–5103; (k) N. Radhoff, C. G. Daniliuc and A. Studer, *Angew. Chem., Int. Ed.*, 2023, **62**, e202304771; (l) J.-J. Wang, L. Tang, Y. Xiao, W.-B. Wu, G. Wang and J.-J. Feng, *Angew. Chem., Int. Ed.*, 2024, **63**, e202405222; (m) J. L. Tyler, F. Schäfer, H. Shao, C. Stein, A. Wong, C. G. Daniliuc, K. N. Houk and F. Glorius, *J. Am. Chem. Soc.*, 2024, **146**, 16237–16247; (n) S. Dutta, Y.-L. Lu, J. E. Erchinger, H. Shao, E. Studer, F. Schäfer, H. Wang, D. Rana, C. G. Daniliuc, K. N. Houk and F. Glorius, *J. Am. Chem. Soc.*, 2024, **146**, 5232–5241; (o) J.-L. Zhou, Y. Xiao, L. He, X.-Y. Gao, X.-C. Yang, W.-B. Wu, G. Wang, J. Zhang and J.-J. Feng, *J. Am. Chem. Soc.*, 2024, **146**, 19621–19628; (p) S. Hu, Y. Pan, D. Ni and L. Deng, *Nat. Commun.*, 2024, **15**, 6128; (q) S. Dutta, D. Lee, K. Ozols, C. G. Daniliuc, R. Shintani and F. Glorius, *J. Am. Chem. Soc.*, 2024, **146**, 2789–2797; (r) Y. Liu, Z. Wu, J.-R. Shan, H. Yan, E.-J. Hao and L. Shi, *Nat. Commun.*, 2024, **15**, 4374; (s) L. Tang, Y. Xiao, F. Wu, J.-L. Zhou, T.-T. Xu and J.-J. Feng, *Angew. Chem., Int. Ed.*, 2023, **62**, e202310066; (t) Y. Xiao, F. Wu, L. Tang, X. Zhang, M. Wei, G. Wang and J.-J. Feng, *Angew. Chem., Int. Ed.*, 2024, **63**, e202408578; (u) M. Xu, Z. Wang, Z. Sun, Y. Ouyang, Z. Ding, T. Yu, L. Xu and P. Li, *Angew. Chem., Int. Ed.*, 2022, **61**, e202214507; (v) T. Yu, J. Yang, Z. Wang, Z. Ding, M. Xu, J. Wen, L. Xu and P. Li, *J. Am. Chem. Soc.*, 2023, **145**, 4304–4310; (w) D. Sarkar, S. Deswal, R. Chandra Das and A. T. Biju, *Chem. Sci.*, 2024, **15**, 16243–16249; (x) Y. Liu, S. Lin, Z. Ding, Y. Li, Y.-J. Tang, J.-H. Xue, Q. Li, P. Li and H. Wang, *Chem*, 2024, **10**, 3699–3708; (y) S. Nicolai and J. Waser, *Chem. Sci.*, 2024, **15**, 10823–10829.
- 12 (a) J. Zhang, J.-Y. Su, H. Zheng, H. Li and W.-P. Deng, *ACS Catal.*, 2024, **14**, 17837–17849; (b) K. Zhang, Z. Gao, Y. Xia, P. Li, P. Gao, X.-H. Duan and L.-N. Guo, *Chem. Sci.*, 2025, **16**, 1411–1416; (c) H. Liao, J. Dong, X. Zhou, Q. Jiang, Z. Lv, F. Lei and D. Xue, *Chem. Sci.*, 2025, **16**, 4654–4660.
- 13 For selected examples of asymmetric peripheral cyclization of BCBs, see: (a) M. de Robichon, T. Kratz, F. Beyer, J. Zuber, C. Merten and T. Bach, *J. Am. Chem. Soc.*, 2023, **145**, 24466–24470; (b) J. Jeong, S. Cao, H.-J. Kang, H. Yoon, J. Lee, S. Shin, D. Kim and S. Hong, *J. Am. Chem. Soc.*, 2024, **146**, 27830–27842; (c) Q. Fu, S. Cao, J. Wang, X. Lv, H. Wang, X. Zhao and Z. Jiang, *J. Am. Chem. Soc.*, 2024, **146**, 8372–8380; (d) F. Wu, W.-B. Wu, Y. Xiao, Z. Li, L. Tang, H.-X. He, X.-C. Yang, J.-J. Wang, Y. Cai, T.-T. Xu, J.-H. Tao, G. Wang and J.-J. Feng, *Angew. Chem., Int. Ed.*, 2024, **63**, e202406548; (e) W.-B. Wu, B. Xu, X.-C. Yang, F. Wu, H.-X. He, X. Zhang and J.-J. Feng, *Nat. Commun.*, 2024, **15**, 8005; (f) X. Wang, R. Gao and X. Li, *J. Am. Chem. Soc.*, 2024, **146**, 21069–21077; (g) X.-G. Zhang, Z.-Y. Zhou, J.-X. Li, J.-J. Chen and Q.-L. Zhou, *J. Am. Chem. Soc.*, 2024, **146**, 27274–27281; (h) Y.-J. Li, Z.-L. Wu, Q.-S. Gu, T. Fan, M.-H. Duan, L. Wu, Y.-T. Wang, J.-P. Wu, F.-L. Fu, F. Sang, A.-T. Peng, Y. Jiang, X.-Y. Liu and J.-S. Lin, *J. Am. Chem. Soc.*, 2024, **146**, 34427–34441; (i) E. F. Plachinski,



- R. Z. Qian, R. Villanueva, D. L. Poole, T. Rosenthal and T. P. Yoon, *J. Am. Chem. Soc.*, 2024, **146**, 31400–31404; (f) X.-C. Yang, F. Wu, W.-B. Wu, X. Zhang and J.-J. Feng, *Chem. Sci.*, 2024, **15**, 19488–19495.
- 14 For selected examples of the difunctionalization of BCBs: (a) J. Majhi, R. K. Dhungana, Á. Rentería-Gómez, M. Sharique, L. Li, W. Dong, O. Gutierrez and G. A. Molander, *J. Am. Chem. Soc.*, 2022, **144**, 15871–15878; (b) K. Das, A. Pedada, T. Singha and D. P. Hari, *Chem. Sci.*, 2024, **15**, 3182–3191.
- 15 For selected examples of the difunctionalization of cyclobutenes: (a) A. K. Simlandy, M.-Y. Lyu and M. K. Brown, *ACS Catal.*, 2021, **11**, 12815–12820; (b) L. Nóvoa, L. Trulli, A. Parra and M. Tortosa, *Angew. Chem., Int. Ed.*, 2021, **60**, 11763–11768; (c) Z. Wang, J. Zhu, M. Wang and P. Lu, *J. Am. Chem. Soc.*, 2024, **146**, 12691–12701.
- 16 (a) M. Silvi and V. K. Aggarwal, *J. Am. Chem. Soc.*, 2019, **141**, 9511–9515; (b) A. Fawcett, T. Biberger and V. K. Aggarwal, *Nat. Chem.*, 2019, **11**, 117–122; (c) S. H. Bennett, A. Fawcett, E. H. Denton, T. Biberger, V. Fasano, N. Winter and V. K. Aggarwal, *J. Am. Chem. Soc.*, 2020, **142**, 16766–16775; (d) H.-C. Shen, M. V. Popescu, Z.-S. Wang, L. de Lescure, A. Noble, R. S. Paton and V. K. Aggarwal, *J. Am. Chem. Soc.*, 2023, **145**, 16508–16516; (e) L. Guo, A. Noble and V. K. Aggarwal, *Angew. Chem., Int. Ed.*, 2021, **60**, 212–216.
- 17 H. Wang, J. E. Erchinger, M. Lenz, S. Dutta, C. G. Daniliuc and F. Glorius, *J. Am. Chem. Soc.*, 2023, **145**, 23771–23780.
- 18 (a) Y. Gaoni, *Tetrahedron Lett.*, 1982, **23**, 5215–5218; (b) S. Hoz, C. Azran and A. Sella, *J. Am. Chem. Soc.*, 1996, **118**, 5456–5461; (c) Y. Gaoni, *Tetrahedron Lett.*, 1982, **23**, 5219–5220; (d) Y. Gaoni, *Tetrahedron Lett.*, 1988, **29**, 1591–1594; (e) Y. Gaoni, A. Tomazic and E. Potgieter, *J. Org. Chem.*, 1985, **50**, 2943–2947; (f) Y. Gaoni, *Tetrahedron*, 1989, **45**, 2819–2840; (g) J. M. Lopchuk, K. Fjelbye, Y. Kawamata, L. R. Malins, C.-M. Pan, R. Gianatassio, J. Wang, L. Prieto, J. Bradow, T. A. Brandt, M. R. Collins, J. Elleraas, J. Ewanicki, W. Farrell, O. O. Fadeyi, G. M. Gallego, J. J. Mousseau, R. Oliver, N. W. Sach, J. K. Smith, J. E. Spangler, H. Zhu, J. Zhu and P. S. Baran, *J. Am. Chem. Soc.*, 2017, **139**, 3209–3226; (h) J. A. Milligan, C. A. Busacca, C. H. Senanayake and P. Wipf, *Org. Lett.*, 2016, **18**, 4300–4303; (i) P. Zhang, R. Zhuang, X. Wang, H. Liu, J. Li, X. Su, X. Chen and X. Zhang, *Bioconjugate Chem.*, 2018, **29**, 467–472; (j) B. D. Schwartz, M. Y. Zhang, R. H. Attard, M. G. Gardiner and L. R. Malins, *Chem. Eur. J.*, 2020, **26**, 2808–2812; (k) K. Tokunaga, M. Sato, K. Kuwata, C. Miura, H. Fuchida, N. Matsunaga, S. Koyanagi, S. Ohdo, N. Shindo and A. Ojida, *J. Am. Chem. Soc.*, 2020, **142**, 18522–18531; (l) A. Kaur, W. Lin, V. Dovhalyuk, L. Driutti, M. L. Di Martino, M. Vujasinovic, J. M. Löhr, M. E. Sellin and D. Globisch, *Chem. Sci.*, 2023, **14**, 5291–5301.
- 19 (a) C. J. Pratt, R. A. Aycock, M. D. King and N. T. Jui, *Synlett*, 2020, **31**, 51–54; (b) H. Gao, L. Guo, C. Shi, Y. Zhu, C. Yang and W. Xia, *Adv. Synth. Catal.*, 2022, **364**, 2140–2145; (c) P.-F. Chen, D.-S. Li, W.-T. Ou, F. Xue and H.-P. Deng, *Org. Lett.*, 2023, **25**, 6184–6188; (d) W. Huang, Y. Zheng, S. Keess and G. A. Molander, *J. Am. Chem. Soc.*, 2023, **145**, 5363–5369; (e) Y. Xiao, T.-T. Xu, J.-L. Zhou, F. Wu, L. Tang, R.-Y. Liu, W.-B. Wu and J.-J. Feng, *Chem. Sci.*, 2023, **14**, 13060–13066.
- 20 X. X. Chang, F. Q. Zhang, S. B. Zhu, Z. Yang, X. M. Feng and Y. B. Liu, *Nat. Commun.*, 2023, **14**, 3876.
- 21 (a) H.-j. Wang, J. B. Gloer, D. T. Wicklow and P. F. Dowd, *J. Nat. Prod.*, 1998, **61**, 804–807; (b) S.-M. Li, *Nat. Prod. Rep.*, 2010, **27**, 57–78; (c) L. Gu, F.-J. Sun, C.-P. Li, L.-T. Cui, M.-H. Yang and L.-Y. Kong, *Phytochem. Lett.*, 2021, **42**, 77–81; (d) Y. Liu, Y. Li, M. Chen, Y. Liu, J. Liang, Y. Zhang and Z.-J. Qian, *Int. Immunopharmacol.*, 2022, **109**, 108931.
- 22 For selected reviews on  $\alpha$ -silylamines as radical precursors: (a) K. Nakajima, Y. Miyake and Y. Nishibayashi, *Acc. Chem. Res.*, 2016, **49**, 1946–1956; (b) A. L. Gant Kanegusuku and J. L. Roizen, *Angew. Chem., Int. Ed.*, 2021, **60**, 21116–21149.
- 23 For selected examples of  $\alpha$ -silylamines as radical precursors: (a) L. Ruiz Espelt, I. S. McPherson, E. M. Wiensch and T. P. Yoon, *J. Am. Chem. Soc.*, 2015, **137**, 2452–2455; (b) R. Kleinmans, L. E. Will, J. L. Schwarz and F. Glorius, *Chem. Sci.*, 2021, **12**, 2816–2822; (c) S. Zheng, W. Wang and W. Yuan, *J. Am. Chem. Soc.*, 2022, **144**, 17776–17782.

